|
American College of Clinical Pharmacy
2003 Spring Practice and Research Forum and 2003 Updates in Therapeutics: The
Pharmacotherapy Preparatory Course
April 27-30, 2003 Palm Springs, CA
-Article by: Kimberly A Galt, PharmD FASHP and Ann M Rule, PharmD
Creighton University, Omaha, NE
Purpose: This study compared the potential for PDA-based drug information sources
to assure medication safety associated with medication errors that are dependent upon
specific, accurate, and complete drug information at the point of care.
Methods: Physicians and pharmacists were surveyed to determine the quality standards
and usefulness of 16 PDA-based drug information sources. Three sources emerged that most
closely met these criteria: Mobile Micromedex, ePocrates,
and Lexi-Drugs. A medication error classification system was then assessed to determine the most common
medication errors types that were likely to occur because of the lack of availability of accurate,
specific, or complete drug information at the point of care. Twenty-six (26) case simulations were
created to test the ability of the sources to meet these safety needs. A rating was assigned to each
resource; 1 = no information, 2 = inadequate information, 3 = adequate information, 4 = information
exceeds need.
Results: The mean ratings for adequacy to meet the information need related to patient safety were
2.9 (Lexi-Drugs), 2.0 (ePocrates), and 2.1 (Mobile Micromedex),
respectively; with Lexi-Drugs significantly better when compared to Mobile Micromedex
(t-test; p = 0.001) and ePocrates (t-test; p = 0.005). No resource was
sufficient for all cases.
Conclusion: Lexi-Drugs was the most accurate, specific, and complete resource
available via PDA to optimize medication safety by reducing potential errors
associated with insufficient or incomplete drug information as a possible cause.
Specific improvements and recommendations to maximize medication safety are discussed.
Support - Agency for Healthcare Research and Quality, Grant #1-R18HS11808-01.
|
Purchase Handheld Software |
|

|
|